14 March 2024
Scancell Holdings
plc
("Scancell" or the "Company")
Appointment of Sath
Nirmalananthan to the Board of Directors
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer
and infectious disease, today announces that Sath Nirmalananthan,
Chief Financial Officer, has been appointed to the Company's Board
of Directors (the "Board") with immediate effect.
Sath was appointed as the Company's
Chief Financial Officer on 29 August 2023, having previously served
as Chief Financial Officer for Europe, Middle-East and Africa at
Prenetics, a leading genomics-driven health sciences company. He
brings more than 15 years' experience in the healthcare sector, and
has held roles at FTSE and NASDAQ listed companies, including
Reckitt and BTG. Prior to this Sath held positions in investment
banking at Nomura, and at KPMG. Sath is a qualified Chartered
Accountant and a member of the Institute of Chartered Accountants
in England and Wales (ICAEW), and sits as a Non-Executive member of
the audit committee at The Institute of Cancer Research (ICR). He
was awarded a BSc in Pharmacology from King's College,
London.
Dr
Jean-Michel Cosséry, Non-Executive Chairman of
Scancell, commented: "Since joining Scancell in August last year,
Sath has brought considerable experience and expertise to the role,
overseeing our successful £12 million fundraise from new and
existing investors. Our focus remains on progressing SCIB1 and
Modi-1 through the clinic whilst also actively seeking
out-licensing, collaborations, and partnerships to accelerate the
development and commercialisation of our products and platforms.
Working closely with the Board, and Executive team, Sath will be
instrumental in driving us towards realising the potential of these
treatments for patients, while creating and delivering significant
long-term value for our shareholders."
Commenting on his new appointment, Sath Nirmalananthan, Chief
Financial Officer and Director of Scancell, said:
"I am proud to take on this expanded role as a
member of the Board, and I look forward to working with my fellow
Board members and the wider team to deliver our goals for 2024 and
beyond. This is an exciting time to be part of Scancell, as we
continue to build significant momentum and approach a number of
important clinical milestones, anticipated later this year,
including further data from both the SCOPE and ModiFY
trials."
Additional Information
In accordance with the AIM Rules,
the following information required to be disclosed in relation to
Sath Nirmalananthan is set out below. Other than this information,
there is no further information required to be disclosed under
paragraph (g) of Schedule Two of the AIM Rules.
Full name and age: Sathijeevan
Nirmalananthan, aged 38
|
|
|
|
Current Directorships
|
Previous Directorships (last 5 years)
|
|
PNSN Company Limited
|
Oxsed Limited
|
|
|
DNA Fit Limited
|
|
|
DNA Sport Limited
|
|
|
DNAFIT Life Sciences
Limited
|
|
|
Prenetics EMEA Limited
|
|
|
Prenetics Consumer Healthcare
Limited
|
|
|
Duo Doc Limited
|
|
|
Norse Medica Limited
|
|
|
SP Care Holdings Limited
|
Mr Sath Nirmalananthan does not have
an interest in any ordinary shares or share options in
Scancell.
|
For
further information, please contact:
|
|
|
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Professor Lindy Durrant,
CEO
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea
(Healthcare Investment Banking)
|
|
|
Nick Adams/Nick Harland (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint Broker)
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate
Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
|
|
|
ICR
Consilium
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Angela
Gray/Lindsey Neville
|
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope® and
ImmunoBody® for vaccines and GlyMab® and
AvidiMab® for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this
includes citrullination and homocitrullination of proteins, whereas
its mAb portfolio targets glycans or sugars that are added onto
proteins and / or lipids (GlyMab®) or enhances the
potency of antibodies and their ability to directly kill tumour
cells (AvidiMab®).
For further information about
Scancell, please visit: https://www.scancell.co.uk/
